

1/11




Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D

3/11




Fig. 2A




Fig. 2B

4/11




Fig. 2C




Fig. 3

5/11

	V1	V2	V3	V4	Post Dosing Period			V7	V8	Follow-Up Period			V11	V12
	Screen	Dose 1	Dose 2		60	90	120		180	270	365			EOS/ET
	-21 (+/-7)	1 ^a	8 ^a	15	(+/-7)	(+/-7)	(+/-7)		(+/-7)	(+/-7)	(+/-7)		540	730
Study Day														(+/-7)
Type of Visit (OV=Office Visit)	OV	In Patient Clinic	In Patient Clinic	OV	OV	OV	OV	OV	OV	OV	OV	OV	OV	OV
Screening and Logistics:														
Informed Consent	X													
Medical And Medication History	X													
Demographics	X													
Complete Physical Exam	X	X	X								X			X
Height	X													
Weight (kg)	X	X												X
Confirm Eligibility Criteria	X	X												
Randomization		X												
Laboratory Assessments:														
Serum Chemistries	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Hematology	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Coagulation	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Urinalysis	X	X	X	X	X	X	X	X	X	X	X	X	X	X
HbsAg, HCV and HIV Serology	X													
Urine Drug Screen	X													
Plasma for Future Research	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Urine Pregnancy Test (WOCBP)	Serum	Urine	Urine				Serum							
Laboratory Assessments: Immune Safety														
Serum Cytokines ^e	X	X ^f	X ^f											

Fig. 4

[illegible]

Fig. 4 (Continued)

- EOS-end of study
- a. Blood Collection pre-dose on Dosing Days.
 - b. Vital signs include temperature, blood pressure and heart rate. Vital signs should be obtained after a 5-minute resting period, and from the opposite arm of the IV line for administration of study drug.
 - c. On Dosing Days, vital signs will be obtained prior to administration of study drug, followed by 15, 30, and 60 minutes after infusion starts, at the end of infusion, and 2 hours and 4 hours after the end of the infusion.
 - d. On Dosing Days, ECG will be obtained prior to administration of study drug and four hours after the end of infusion.
 - e. Serum cytokines: IL-1 β , TNF- α , IL-6, MCP-1, I MIP-1 α , IFN- γ , IL-4, IL-10.
 - f. Serum cytokines will be obtained prior to dose and 4 hours after the end of the infusion.
 - g. A blood sample for tryptase will be obtained if a patient has an infusion or anaphylactic reaction. This sample will be obtained within two hours but not beyond four hours of the infusion or anaphylactic event.
 - h. Baseline healthcare utilization is reported as hospital use (MG exacerbation rate requiring rescue therapy with IVIG/PLEX) within 1 year of study start.
 - i. On Days 90 Through 730, blood for antigen specific CD4+ and CD8+ T cells will be collected only for subjects with a positive response any time prior to or on Day 60.

Fig. 4 (Continued)

Patient ID	HLA-DRB1*03 status	HLA-DRB3*01 status	HLA-DQB1*02 status
116873	Negative	Negative	Positive
116790	Negative	Positive	Negative
117317	Negative	Negative	Positive
125995*	Negative	Negative	Negative
125673*	Negative	Negative	Negative
126006	Positive	Positive	Positive
113904	Negative	Negative	Positive
113953	Positive	Positive	Positive
114739	Negative	Positive	Positive
126117	Negative	Negative	Positive

Fig. 5




Fig. 6

10/11




Fig. 6 (Continued)


11/11

Fig. 7